Thrombocytopenia   

Questions discussed in this category



Such as the case in which a patient is unresponsive to steroids, IVIG, TPO-agonist, rituximab, splenectomy, and even fostamitinib.

How often do you monitor ADAMTS-13 levels off therapy?

For example, do we prefer one regimen over the other in patients with a bleeding history or who have relapsed after a lengthy remission?

Does having a concurrent consumptive process e.g. DIC change your management? 

Would you consider high-dose dexamethasone (deliberating adverse effects of antenatal steroids) or move to next-line therapies?

At what point would you recommend transfusion? At what point would you stop radiation?


Papers discussed in this category


Blood, 2015 May 13

Blood, 2009 Nov 06

Blood,

J Pharm Pract, 2019 Mar 27